Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.61 |
| ▸ | KDR | P35968 | 1/20 | 0.61 |
| ▸ | FLT3 | P36888 | 1/20 | 0.61 |
| ▸ | PIM1 | P11309 | 2/20 | 0.60 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.60 |
| ▸ | PRKCA | P17252 | 2/20 | 0.58 |
| ▸ | PRKACA | P17612 | 2/20 | 0.58 |
| ▸ | PRKACG | P22612 | 2/20 | 0.58 |
| ▸ | PRKACB | P22694 | 2/20 | 0.58 |
| ▸ | PRKCB | P05771 | 1/20 | 0.56 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.56 |
| ▸ | CDK4 | P11802 | 1/20 | 0.56 |
| ▸ | CCND1 | P24385 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30319768 | 1.00 | GSK3B (0.61) | GSK3BKDRFLT3PIM1CAMK2D | |
| SCHEMBL14555040 | 0.89 | CCNE2 (0.66) | GSK3BPRKCACDK4CCND1 | |
| SCHEMBL3139598 | 0.86 | GSK3B (0.78) | GSK3BPIM1CAMK2DPRKCAPRKACA | |
| SCHEMBL14041601 | 0.86 | GSK3B (0.66) | GSK3BKDRFLT3PIM1CAMK2D | |
| SCHEMBL6950855 | 0.83 | CCNE2 (0.66) | GSK3BKDRPRKCACDK4CCND1 | |
| SCHEMBL3150613 | 0.83 | PIM1 (0.77) | GSK3BPIM1CAMK2DPRKCAPRKACA | |
| SCHEMBL5686033 | 0.83 | GSK3B (0.66) | GSK3BKDRFLT3PIM1CAMK2D | |
| SCHEMBL8166369 | 0.82 | PIM1 (0.75) | GSK3BPIM1CAMK2DPRKCAPRKACA | |
| SCHEMBL7873644 | 0.81 | PRKACA (0.80) | GSK3BKDRFLT3PIM1CAMK2D | |
| SCHEMBL5682666 | 0.81 | GSK3B (0.62) | GSK3BPIM1CAMK2DPRKCAPRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2020-07-02 | — | — | US | claimed |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2016-08-25 | — | — | US | claimed |
| US-20150087687-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS (US) | 2015-03-26 | — | — | US | claimed |
| EP-2827869-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | Brown, Dennis (US) | 2015-01-28 | — | — | EP | claimed |
| WO-2013142817-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS (US) | 2013-09-26 | — | — | WO | claimed |
| US-20060217368-A1 | Drug for nerve regeneration | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-28 | — | — | US | claimed |
| EP-1645286-A1 | DRUG FOR NERVE REGENERATION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-04-12 | — | — | EP | claimed |
| EP-1140070-A1 | TREATMENT OF CONDITIONS WITH A NEED FOR THE INHIBITION OF GSK-3 | SMITHKLINE BEECHAM PLC (GB) | 2001-10-10 | — | — | EP | claimed |
| WO-2000038675-A1 | TREATMENT OF CONDITIONS WITH A NEED FOR THE INHIBITION OF GSK-3 | SMITHKLINE BEECHAM PLC (GB) | 2000-07-06 | — | — | WO | claimed |
| US-20230100193-A1 | NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME | CYTODIGM, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20200383931-A1 | NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME | CYTODIGM, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2020-07-02 | — | — | US | disclosed |
| EP-3600259-A1 | NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME | Phosphorex, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| CN-110709066-A | Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same | 法斯瑞斯公司 | 2020-01-17 | — | — | CN | disclosed |
| WO-2005028678-A9 | METHODS AND MATERIALS FOR IDENTIFYING AGENTS WHICH MODULATE BONE REMODELING AND AGENTS IDENTIFIED THEREBY | WYETH CORP (US) | 2006-08-31 | — | — | WO | disclosed |
| EP-1645286-A1 | DRUG FOR NERVE REGENERATION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-04-12 | — | — | EP | disclosed |
| EP-1636388-A2 | METHODS AND MATERIALS FOR IDENTIFYING AGENTS WHICH MODULATE BONE REMODELING AND AGENTS IDENTIFIED THEREBY | Wyeth (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005028678-A2 | METHODS AND MATERIALS FOR IDENTIFYING AGENTS WHICH MODULATE BONE REMODELING AND AGENTS IDENTIFIED THEREBY | WYETH (US) | 2005-03-31 | — | — | WO | disclosed |
| EP-1140070-A1 | TREATMENT OF CONDITIONS WITH A NEED FOR THE INHIBITION OF GSK-3 | SMITHKLINE BEECHAM PLC (GB) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000038675-A1 | TREATMENT OF CONDITIONS WITH A NEED FOR THE INHIBITION OF GSK-3 | SMITHKLINE BEECHAM PLC (GB) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230100193-A1 | NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME | UGT2B7, UGT1A7, CYP3A7 | GSK3B 387/4885KDR 3334/4885FLT3 1926/4885 |
| US-20060217368-A1 | Drug for nerve regeneration | GSK3A, BDNF, GSK3B | GSK3B 3/4885KDR 1689/4885FLT3 2100/4885 |
| US-20200383931-A1 | NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME | UGT2B7, UGT1A7, CYP3A7 | GSK3B 387/4885KDR 3334/4885FLT3 1926/4885 |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | GSK3B 37/4885KDR 4228/4885FLT3 3630/4885 |
| US-20150087687-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | CYP7A1, CYP3A7, UGT2B7 | GSK3B 222/4885KDR 3908/4885FLT3 1413/4885 |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | GSK3B 37/4885KDR 4228/4885FLT3 3630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.